Literature DB >> 24196921

Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine.

Frederik A Verburg1, Alexander Heinzel, Heribert Hänscheid, Felix M Mottaghy, Markus Luster, Luca Giovanella.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24196921     DOI： 10.1007/s00259-013-2609-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  28 in total

Review 1.  Theranostics: evolution of the radiopharmaceutical meta-iodobenzylguanidine in endocrine tumors.

Authors:  James C Sisson; Gregory A Yanik
Journal:  Semin Nucl Med       Date:  2012-05       Impact factor: 4.446

2.  Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Authors:  Shengri Liao; Bill C Penney; Kristen Wroblewski; Hao Zhang; Cassie A Simon; Rony Kampalath; Ming-Chi Shih; Naoko Shimada; Sheng Chen; Ravi Salgia; Daniel E Appelbaum; Kenji Suzuki; Chin-Tu Chen; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-23       Impact factor: 9.236

3.  Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients.

Authors:  Frederik A Verburg; Bart de Keizer; Cornelis J M Lips; Pierre M J Zelissen; John M H de Klerk
Journal:  Eur J Endocrinol       Date:  2005-01       Impact factor: 6.664

4.  CLINICAL STUDIES WITH THE AID OF RADIOACTIVE PHOSPHORUS. I. THE ABSORPTION AND DISTRIBUTION OF RADIO-PHOSPHORUS IN THE BLOOD AND ITS EXCRETION BY NORMAL INDIVIDUALS AND PATIENTS WITH LEUKEMIA.

Authors:  L A Erf; J H Lawrence
Journal:  J Clin Invest       Date:  1941-09       Impact factor: 14.808

5.  No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.

Authors:  Frederik Anton Verburg; Marcel P M Stokkel; Christian Düren; Robbert B T Verkooijen; Uwe Mäder; Johannes W van Isselt; Robert J Marlowe; Johannes W Smit; Christoph Reiners; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-29       Impact factor: 9.236

6.  Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.

Authors:  Andreas Helisch; Gregor J Förster; Helmut Reber; Hans-Georg Buchholz; Rudolf Arnold; Burkhard Göke; Matthias M Weber; Bertram Wiedenmann; Stanislas Pauwels; Ulrike Haus; Hakim Bouterfa; Peter Bartenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-03       Impact factor: 9.236

7.  Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.

Authors:  Martin J Edelman; Wael A Harb; Sridhar E Pal; Ralph V Boccia; Michael J Kraut; Philip Bonomi; Barbara A Conley; John S Rogers; Richard A Messmann; Edward B Garon
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

8.  EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy.

Authors:  Michael Lassmann; Heribert Hänscheid; Carlo Chiesa; Cecilia Hindorf; Glenn Flux; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07       Impact factor: 9.236

9.  Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions.

Authors:  Frank Willi Floeth; Michael Sabel; Gabriele Stoffels; Dirk Pauleit; Kurt Hamacher; Hans-Jakob Steiger; Karl-Josef Langen
Journal:  J Nucl Med       Date:  2008-04-15       Impact factor: 10.057

10.  Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.

Authors:  M de Jong; W H Bakker; E P Krenning; W A Breeman; M E van der Pluijm; B F Bernard; T J Visser; E Jermann; M Béhé; P Powell; H R Mäcke
Journal:  Eur J Nucl Med       Date:  1997-04
View more
  4 in total

1.  Why should we be concerned about a "g"?

Authors:  Savvas Frangos; John R Buscombe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-11-06       Impact factor: 9.236

2.  Current Status and Growth of Nuclear Theranostics in Singapore.

Authors:  Hian Liang Huang; Aaron Kian Ti Tong; Sue Ping Thang; Sean Xuexian Yan; Winnie Wing Chuen Lam; Kelvin Siu Hoong Loke; Charlene Yu Lin Tang; Lenith Tai Jit Cheng; Gideon Su Kai Ooi; Han Chung Low; Butch Maulion Magsombol; Wei Ying Tham; Charles Xian Yang Goh; Colin Jingxian Tan; Yiu Ming Khor; Sumbul Zaheer; Pushan Bharadwaj; Wanying Xie; David Chee Eng Ng
Journal:  Nucl Med Mol Imaging       Date:  2019-01-25

Review 3.  The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer-A Practical Clinical Review.

Authors:  Anna Rebecca Lisney; Conrad Leitsmann; Arne Strauß; Birgit Meller; Jan Alexander Bucerius; Carsten-Oliver Sahlmann
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575

4.  The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model.

Authors:  Nusrat J Begum; Gerhard Glatting; Hans-Jürgen Wester; Matthias Eiber; Ambros J Beer; Peter Kletting
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.